Biotech Startups

Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.

2 investors

Stellular Bio develops platelet-derived regenerative biologic (PRB) therapeutics to treat ocular surface disease, initially targeting Sjogren's syndrome-related dry eye. The company has demonstrated efficacy in animal models and is advancing its lead candidate toward clinical testing.

2 investors

STENTiT is a Dutch medtech company developing the Resorbable Fibrillated Scaffold (RFS), a device designed to trigger natural healing and reconstruct arteries for treating vascular conditions. The technology initially targets below-the-knee chronic limb threatening ischemia and has broader applications across endovascular treatments.

2 investors

Stimdia Medical develops neuromodulation technologies, with a leadership team focused on clinical and regulatory affairs and R&D in critical care and pulmonary medicine. The company operates in the medical device sector.

2 investors

StimOxyGen develops advanced nanoparticle-based therapies using sonodynamic and oxygen-generating technology for oncology and wound healing. The company focuses on addressing unmet medical needs in cancer treatment and tissue regeneration.

2 investors

Stingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.

2 investors

Stirling Ultracold builds ultra-low temperature (ULT) freezers based on free-piston Stirling engine technology, offering high-density storage with lower energy consumption than conventional units. Its freezers serve research labs, hospitals, and cancer centers, and are sold directly and through laboratory supply distributors worldwide.

2 investors

Stream Biomedical is a clinical-stage biotechnology company developing LG3, a biologic derived from a natural repair protein intended to protect and restore the brain by activating its repair systems. Its lead program targets Alzheimer's disease and related dementias, with potential use in stroke, traumatic brain injury, and other neurological conditions.

2 investors

StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases. The company focuses on drug development and AAV manufacturing in the gene therapy field.

2 investors

SugaROx develops precision crop biostimulants using patented chemical-caging technology to deliver single-molecule formulations that improve plant metabolism and stress responses, targeting staple crops including wheat, barley, soybean, and maize for agricultural markets.

2 investors

Sun Bear Biofuture develops genetically modified yeast that produces oil through precision fermentation for sustainable food production. The company targets the fats and oils industry with a focus on reducing environmental impact from conventional agriculture.

2 investors

Flore creates personalized probiotics based on individual microbiome sequencing, analyzing gut health markers to formulate targeted probiotic blends for each customer. The company serves consumers seeking customized solutions for digestive and gut-brain health issues.

2 investors

Sunstone Therapies is a clinical research organization with expertise in psychedelic and consciousness research, operating with teams that include researchers from institutions like Johns Hopkins Center for Psychedelic and Consciousness Research and the Dana-Farber Cancer Institute. The company focuses on patient-centered care with clinical rigor in the mental health and oncology spaces.

2 investors

Superbrewed Food produces SB1, an FDA-GRAS postbiotic cultured protein ingredient made through anaerobic fermentation of bacteria, offering a non-GMO, high-protein alternative for use in food and beverage products such as cheese and meat alternatives. The company sells the ingredient to food manufacturers and has collaborated with partners including Fonterra, Bel, and Döhler.

2 investors

Uses ML and big data to accelerate drug development.

2 investors

Supernus is a pharmaceutical company that develops and markets products in the biosciences and pharmaceutical industry. This page lists awards and recognitions the company has received for growth, workplace, and performance.

2 investors

Surf Bio is a preclinical biopharmaceutical company developing its SnapShot technology, which uses a proprietary polymer to create ultra-high-concentration antibody and biologic formulations (600+ mg/mL, doses over 1,000 mg) for delivery via a standard autoinjector. The technology enables at-home subcutaneous self-injection of monoclonal antibodies and biologics as an alternative to in-clinic IV infusion, and is offered to pharmaceutical API manufacturers through partnerships.

2 investors

Sword Bio is a bioanalytical contract research organization providing assay development and testing services for pharmaceutical and biotechnology companies across preclinical through Phase IV clinical trials. The company specializes in pharmacokinetics, biomarker analysis, and immunogenicity assessment for large molecule, gene therapy, and cell therapy biotherapeutics.

2 investors

Sylvatica Bio develops organ and tissue preservation technologies, including supercooling methods that extend the viability of human organs such as livers outside the body. Its work targets transplantation, regenerative medicine, and drug discovery within biomedicine.

2 investors

Symeres provides pharmaceutical quality management systems, drug discovery and development services, and contract manufacturing support for biotech and pharma companies. The company operates GMP, GLP, and ISO-certified facilities across Europe and North America to support molecules from early discovery through regulatory submission and manufacturing.

2 investors

Symphorna is developing a therapeutic platform for multi-RNA combination medicines that deliver combined mRNAs and siRNAs alongside a predictive design loop to target multiple disease pathways at once. It focuses on complex conditions such as fibrosis, heart failure, and neurodegeneration, with lung fibrosis as its initial proving ground.

2 investors

Synakis develops ocular biomaterials, including its lead candidate SNK-125, through pre-clinical research and a pipeline of eye-related products. The company operates in the ophthalmic biomaterial and biotech space.

2 investors

Synapse Biomedical develops and commercializes neurostimulation medical devices, including the NeuRx Diaphragm Pacing System (DPS), which uses electrical stimulation of the diaphragm to treat chronic respiratory insufficiency in patients with spinal cord injuries and ALS. The company serves clinicians and patients dependent on mechanical ventilation.

2 investors

Synaptrix develops NOVABLOC, a non-opioid neuromodulation therapy that uses electrical stimulation to provide targeted, long-lasting postoperative pain relief. The device is being evaluated in a US randomized controlled trial for perioperative pain management, aiming to reduce opioid use after surgeries such as knee replacement.

2 investors